New partnership expands ARS Pharma’s direct promotional efforts to nearly 20,000 healthcare providers, reaching key pediatricians ahead of the back-to-school season

 ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced that the company has entered into an agreement with ALK-Abelló A/S to co-promote neffy® , the only approved needle-free treatment for Type I allergic reactions including anaphylaxis, to up to 9,000 pediatricians. This agreement accelerates ARS Pharma’s efforts to reach these key prescribers prior to the back-to-school season.

“As a result of broad coverage from leading pharmaceutical benefit managers and health plans, millions of patients nationwide now have improved access to neffy,” said Richard Lowenthal, Co-Founder, President, and CEO of ARS Pharma. “This partnership extension with ALK allows us to efficiently reach healthcare professionals who represent about 55% of all community-use epinephrine prescriptions in the United States. By expanding direct promotion with ALK, the global leader in allergy immunotherapy (AIT) with substantial experience in the allergy space, we can ramp up quickly ahead of the peak summer season to ensure neffy is optimally positioned as a needle-free, safe and effective treatment option for children with severe allergic reactions.”

Health Technology Insights: Altesa BioSciences announces Katharine Knobil, M.D. as Chief Medical Officer

“We are excited about expanding our partnership with ARS Pharma,” said Peter Halling, ALK President and CEO. “We firmly believe that this will prove to be a win-win situation for all parties. More children, caregivers, and prescribers in the U.S. get access to an effective and needle-free anaphylaxis treatment, and this partnership complements our existing allergy immunotherapy portfolio.”

Under the terms of the four-year deal, ARS Pharma will recognize all U.S. revenue and continue to have sole responsibility for all U.S. commercialization activities including marketing, medical affairs, market access, production, distribution, pharmacovigilance, quality and safety. Other key terms of the agreement include:

Health Technology Insights: AI Mapping Tech Unfold Outperforms MRI in Prostate Cancer

  • neffy will be in the primary position for ALK sales representatives during the first two years of the agreement, and co-primary position during the last two years of the agreement.
  • ARS Pharma will compensate ALK for its costs of the ALK sales force promotion activities through payment of a quarterly base fee.
  • ALK will be eligible for performance-based payments based upon exceeding certain market share thresholds starting in the second year of the partnership. These payments in year two of the agreement are equal to 30% of the net revenue that is in excess of a specified initial market share threshold for neffy prescriptions written by target pediatrician prescribers. That specified initial market share threshold increases to a threshold of 50% market share during years three and four of the partnership.
  • ARS Pharma retains the option to terminate the partnership at any time upon a change of control, in addition to other termination option rights.

“As the second quarter begins, families nationwide are meeting with healthcare providers to explore treatment options that help protect children from allergic reactions ahead of the back-to-school season,” continued Lowenthal. “Alongside our expanded pediatrician sales initiative, we’re launching a direct-to-consumer campaign in May to coincide with the availability of the 1 mg dose for children over four years who weigh at least 33 pounds. We also anticipate broadening unrestricted commercial access for neffy over the summer, ensuring a smooth prescribing experience for patients and physicians.”

ARS Pharma expects its operating expense guidance for financial year 2025 to increase by approximately $3 million per quarter starting in the third quarter of 2025. ARS Pharma’s 2025 cash flow will not be impacted.

Health Technology Insights: ThinkAndor AI Software Infrastructure for Healthcare Delivers Significant Virtual Nursing ROI

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source – GlobeNewswire